medigraphic.com

2020, Number 2

<< Back Next >>

Rev Hematol Mex 2020; 21 (2)

Analysis of cost minimization between two treatments on demand of hemophilia A in children in Mexico. Are the cryoprecipitates a cheaper option?

Salinas-Escudero G, Castillo-Martínez ID, Martínez-Valverde S, Garduño-Espinosa J, Carrillo-Vega MF

Language: Spanish
References: 26
Page: 92-102
PDF size: 244.98 Kb.


ABSTRACT

Background: Hemophilia A is a hereditary hemorrhagic disease whose treatment is expensive and in countries with limited resources can represent a challenge for health service.
Objective: To compare the potential costs of two treatment on demand in patients with hemophilia A: management with FVIII versus cryoprecipitates.
Material and Method: A cost minimization analysis was developed in September 2019, considering the scenarios of hemarthrosis and intracranial hemorrhage in population ‹ 18 years with diagnosis of hemophilia A and treatment on demand. The treatment comparators were management with FVIII versus cryoprecipitates. The costs are presented in US dollars (2018).
Results: Total annual costs for hemarthrosis were between 5020-12,557 for management with FVIII and 10,577-51,503 for cryoprecipitates. In the case of intracranial hemorrhage, the cost per event was between 9655-47,573 for management with FVIII and 16,082-87,703 for cryoprecipitates. In both scenarios the results depended on the patient’s age.
Conclusions: The cryoprecipitate option represented an increase in costs of 110- 310% compared to management with FVIII in the case of hemarthrosis, and 66%-84% in intracranial hemorrhages compared to management with FVIII. The use of cryoprecipitates was ruled out due to the increase in cost and risk of infectious diseases.


REFERENCES

  1. World Federation of Hemophilia. Report on the Annual Global Survey 2015. Montreal, Quebec, Canadà: World Federation of Hemophilia; 2016.

  2. Secretaría de Salud. Diagnóstico y tratamiento de Hemofilia Pediátrica. Actualizacion 2012. México: Secretaría de Salud; 2012.

  3. Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet (London, England). 2003;361(9371):1801-9. DOI: 10.1016/ S0140-6736(03)13405-8.

  4. Federación Mundial de Hemofilia. Guías para el tratamiento de la hemofilia. 2012.

  5. World Federation of Hemophilia. Transtornos de la coagulación 2018 [updated marzo 2016. Available from: https:// www.wfh.org/es/page.aspx?pid=781.

  6. World Federation of Hemophilia. Report on the Annual Global Survey 2016. Montreal, Quebec, Canadà: World Federation of Hemophilia; 2017 October 2017.

  7. Björkman SBE. Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Clin Pharmacokin 2001;40(11):815-32. DOI: 10.2165/00003088- 200140110-00003.

  8. Carlos-Rivera F, Gasca-Pineda R, Majluf-Cruz A, Garcia- Chavez J. [Economic impact of hemophilia type A and B in Mexico]. Gac Med Mex 2016;152(1):19-29.

  9. Srivastava A BA, Mauser-Bunschoten EP, Key NS, Kitchen S, Llinas A, Ludlam CA, Mahlangu JN, Mulder K, Poon MC, Street A. Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. Guidelines for the management of hemophilia. Haemophilia 2013;19(1):e1- 47. 10.1111/j.1365-2516.2012.02909.x.

  10. Centro Nacional de Estadísticas de Salud en colaboración con el Centro Nacional para la Prevención de Enfermedades Crónicas y Promoción de Salud. Nacimiento a 36 meses: Niños Percentiles de Estatura por edad y Peso por edad. 2001.

  11. Centro Nacional de Estadísticas de Salud en colaboración con el Centro Nacional para la Prevención de Enfermedades Crónicas y Promoción de Salud. 2 a 20 años: Niños Percentiles de Estatura por edad y Peso por edad. 2001.

  12. Hospital Infantil de México Federico Gómez. Tabulador de Cuotas de Recuperación 2017. 2017.

  13. Instituto Nacional de Pediatría. Tabulador de Cuotas de Recuperación 2018. México: Instituto Nacional de Pediatría, Secretaría de Salud; 2018.

  14. Instituto Mexicano del Seguro Social Grupos Relacionados con el Diagnóstico: Producto Hospitalario GRD-IMSS: 2014. IMSS, editor. México 2014. 478 p.

  15. Sistema de Información Económica. Serie Histórica del Tipo de cambio [Internet]. Banxico. 2018 [cited 22/08/2018]. Available from: http://www.banxico.org.mx/SieInternet/ consultarDirectorioInternetAction.do?sector=6&idCuadr o=CF373&accion=consultarCuadro&locale=es.

  16. (CSG) CdSG. Guía para la Conducción de Estudios de Evaluación Económica para la Actualización del Cuadro Básico y Catálogo de Insumos del Sector Salud en México. In: de CIdCByC, Salud IdS, editors. México: Consejo de Salubridad General; 2015. p. 1-56.

  17. Sistema de Informacion Económica. Índices de Precios al Consumidor y UDIS [Internet]. Banco Nacional de México. 2018 [cited 20 Agosto 2018]. Available from: http://www. banxico.org.mx/SieInternet/consultarDirectorioInternetAction. do?accion=consultarCuadro&idCuadro=CP154& locale=es.

  18. Yee TT, Lee CA, Pasi KJ. Life-threatening human parvovirus B19 infection in immunocompetent haemophilia. Lancet (London, England) 1995;345(8952):794-5. DOI: 10.1016/ s0140-6736(95)90673-8.

  19. Ludlam CA, Powderly WG, Bozzette S, Diamond M, Koerper MA, Kulkarni R, et al. Clinical perspectives of emerging pathogens in bleeding disorders. Lancet (London, England) 2006;367(9506):252-61. https://doi.org/10.1016/S0140- 6736(06)68036-7.

  20. Di Minno A, Canaro MI, Ironside JW, et al. Pathogen safety of long-term treatments for bleeding disorders: (un)predictable risks and evolving threats. Semin Thromb Hemost 2013;47(5):779-93. doi: 10.1055/s-0033-1354420.

  21. Farrugia A. Safety issues of plasma-derived products for treatment of inherited bleeding disorders. Sem Thromb Hemostasis 2016;42(5):583-8. doi: 10.1055/s-0036-1571314.

  22. Geng Y, Wu CG, Bhattacharyya SP, Tan D, Guo ZP, Yu MY. Parvovirus B19 DNA in Factor VIII concentrates: effects of manufacturing procedures and B19 screening by nucleic acid testing. Transfusion 2007;47(5):883-9. DOI: 10.1111/j.1537-2995.2007.01205.x.

  23. Evatt B, Austin H, Leon G, Ruiz-Saez A, de Bosch N. Hemophilia treatment. Predicting the long-term risk of HIV exposure by cryoprecipitate. Haemophilia 2000;6 Suppl 1:128-32. DOI: 10.1046/j.1365-2516.2000.00057.x.

  24. Arroyo A TH, Estrada C, Rojo J. Estimated risk for transfusion transmitted infectious diseases in Mexico. Vox Sanguinis 2011;101(Suppl. 1):194.

  25. Zou S, Stramer SL, Notari EP, Kuhns MC, Krysztof D, Musavi F, et al. Current incidence and residual risk of hepatitis B infection among blood donors in the United States. Transfusion 2009;49(8):1609-20. DOI: 10.1111/j.1537-2995.2009.02195.x.

  26. Zou S, Musavi F, Notari EP, Stramer SL, Dodd RY. Prevalence, incidence, and residual risk of major blood-borne infections among apheresis collections to the American Red Cross Blood Services, 2004 through 2008. Transfusion 2010;50(7):1487-94.




2020     |     www.medigraphic.com